Tumor News and Research

RSS

Scientists compared 51 longevity studies to see which aging biomarkers respond most reliably

Researchers analyzing 51 longitudinal intervention studies found that reliable generation 2+ DNA methylation biomarkers, particularly those predicting mortality or pace of aging, were the most responsive to interventions aimed at longevity or healthspan. Pharmacological and lifestyle interventions produced the strongest biomarker changes, but the authors cautioned that responsiveness does not yet establish these measures as validated surrogate endpoints for slower aging or longer life.

25 Aug 2026

Could a daily vinegar drink help with constipation? A small trial offers a clue

A randomized, double-blind trial found that adults with mild constipation who drank a vinegar beverage daily for four weeks had more frequent bowel movements than those receiving placebo. Exploratory findings also suggested earlier improvements in bowel habits, although the small feasibility-based trial requires confirmation in larger and more diverse populations.

24 Aug 2026

Targeting cyclin-dependent kinases offers new pathways for cancer therapy

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus.

24 Aug 2026

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases.

21 Aug 2026

Antibodies for visualizing cell identity and tumor architecture

Whether you are characterizing cell state transitions, assessing organelle integrity, or building a multiplex immunofluorescence (IF) assay, you need reliable structural markers for your imaging.

From Antibodies Incorporated 21 Aug 2026

Scientists identify molecule driving one of the deadliest forms of breast cancer

Australian researchers have uncovered a promising new way to tackle one of the most aggressive forms of breast cancer, raising hopes for more effective treatments to stop the disease from spreading.

21 Aug 2026

Younger lung cancer patients show more targetable gene alterations

Younger adults with non-small cell lung cancer are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.

21 Aug 2026

Scientists uncover safer way to tame cancer cell senescence

Stopping tumor growth is only half the battle. Rather than kill tumor cells, many cancer therapies can only push them into cellular senescence, a state in which cells stop dividing but do not die. These "undead" cells will continue to release signals that reshape the tumor environment.

20 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Study shows how prostate tumors rewire metabolism to resist therapy

Prostate tumors can rewire amino acid metabolism to override the normal brakes on cholesterol production, a process that may fuel hormone therapy resistance, according to a study by Weill Cornell Medicine investigators.

20 Aug 2026

FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation

FairJourney Bio ("FJBio"), a global antibody discovery expert, today announced the publication of a peer-reviewed study in mAbs describing a novel approach with the potential to improve the therapeutic window of IL-12, a potent anti-tumor cytokine.

From FairJourney Biologics 20 Aug 2026

New studies reveal hidden control hub for MYC-driven cancers

In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, PhD, associate professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys Medical Discovery Institute, establish a unified framework that governs one of cancer's most powerful master regulators.

19 Aug 2026

Colorectal tumors may damage nerves before chemotherapy

Researchers at The University of Texas MD Anderson Cancer Center found that, in preclinical models of colorectal cancer, tumors can start damaging peripheral nerves before chemotherapy begins.

19 Aug 2026

Multi-organ chip uncovers key mechanisms behind cancer metastasis

Cancer spreading beyond the primary tumor – a process known as metastasis – is responsible for at least two-thirds of cancer deaths.

19 Aug 2026

Skull bone marrow contains immune hubs that fight brain cancer

Researchers at Washington University School of Medicine in St. Louis have discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer before distant lymph nodes get the signal that abnormal cells are present.

19 Aug 2026

Red blood cells inspire next-generation therapeutic nanocarriers

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

19 Aug 2026

Researchers put olive and fish oil IV nutrition under the microscope

A systematic review of six randomized trials compared olive-oil-based and fish-oil-containing parenteral nutrition in hospitalized adults, examining infection, inflammation, oxidative stress, liver function, and clinical outcomes. The included studies involved diverse patient groups and lipid formulations, with substantial variation in outcomes and insufficient evidence for a meta-analysis.

18 Aug 2026